𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B

✍ Scribed by E. Dimou; G.V. Papatheodoridis; A. Laras; S.J. Hadziyannis

Book ID
119526044
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
148 KB
Volume
32
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Efficacy of lamivudine in HBeAg-negative
Efficacy of lamivudine in HBeAg-negative chronic hepatitis B
✍ Mario Rizzetto πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 136 KB

## Abstract Hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg. It accounts for 7–30% of patients with chronic hepatitis B virus (HBV) worldwide, with the highest rates reported for Mediterranean Europe and Asia.

Long-term lamivudine therapy for childre
Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B
✍ Etienne M. Sokal; Deirdre A. Kelly; Jacek Mizerski; Isabel B. Badia; Jorge A. Ar πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 1 views

One year of lamivudine treatment results in increased hepatitis B e antigen (HBeAg) seroconversion and serum hepatitis B virus (HBV) DNA negativity in children with chronic hepatitis B and high serum alanine aminotransferase concentrations. Two hundred seventy-six children who participated in a 1-ye